AFMD - Affimed begins patient recruitment for phase 1/2a trial of cancer treatment

Affimed (NASDAQ:AFMD) has begun patient recruitment for a proof of concept trial of AFM24 in combination with NKGen Biotech's SNK01. AFM 24 is a epidermal growth factor receptor ("EGFR")  and CD16A-binding innate cell engager, while SNK01 is an autologous NK cell therapy made from a patient's whole blood. Affimed says phase 2 trials will include patients with non-small cell lung cancer, squamous cell carcinoma of the head and neck, and colorectal cancer. Seeking Alpha contributor Biologics, who has a bullish rating on shares, recently wrote that Affimed has several catalysts next year that could propel the company's outlook.

For further details see:

Affimed begins patient recruitment for phase 1/2a trial of cancer treatment